Oxygen-affinity modulator for sickle cell disease to generate $1.8bn sales by 2025

Figure 1: Forecast annual sales of Oxbryta vs late-stage pipeline drugs for sickle cell disease, 2020-2025. Source: GlobalData, Pharma Intelligence Center.